BioCardia (NASDAQ: BCDA) CEO buys 5,000 shares at $0.78

Rhea-AI Filing Summary

BioCardia, Inc. reports that President and CEO Peter Altman purchased 5,000 shares of common stock on July 29, 2026 at a weighted average price of $0.78 per share, executed in multiple trades between $0.77 and $0.80. Following this transaction, he directly holds 373,885 shares.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 5,000 shs ($4K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	5,000	$0.78	$4K

Holdings After Transaction: Common Stock — 373,885 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades ranging from $0.77 to $0.80 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased: 5,000 shares Weighted average purchase price: $0.7800 per share Trade price range: $0.77 to $0.80 per share +1 more

4 metrics

Shares purchased 5,000 shares Common stock purchase on 2026-07-29

Weighted average purchase price $0.7800 per share Reported weighted average for the 5,000-share transaction

Trade price range $0.77 to $0.80 per share Range of prices across multiple trades in the purchase

Post-transaction holdings 373,885 shares Direct ownership after the reported purchase

Key Terms

weighted average per share sales price, open market or private transaction

2 terms

weighted average per share sales price financial

"The price reported above reflects the weighted average per share sales price."

open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 09:05 PM Accepted by SEC EDGAR 07/29/2026 - 09:05 PM Learn about SEC filing dates

FAQ

What insider transaction did BioCardia (BCDA) report for Peter Altman?

BioCardia reported that CEO Peter Altman bought 5,000 shares of common stock on July 29, 2026. The shares were acquired in multiple trades, all part of a single reported purchase transaction.

How many BioCardia (BCDA) shares did the CEO buy and at what price?

CEO Peter Altman purchased 5,000 shares of BioCardia common stock at a weighted average price of $0.78 per share. The trades were executed in a price range from $0.77 to $0.80 per share.

What is Peter Altman’s total BioCardia (BCDA) shareholding after this trade?

After the reported purchase, Peter Altman directly holds 373,885 shares of BioCardia common stock. This figure reflects his direct ownership position immediately following the July 29, 2026 transaction.

Over what price range were BioCardia (BCDA) shares bought in this insider trade?

The 5,000 shares were purchased in multiple trades ranging between $0.77 and $0.80 per share. The Form 4 reports a weighted average price of $0.78 per share for the overall transaction.

Was the BioCardia (BCDA) CEO’s share purchase under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox was not selected, so the transaction is not identified as made under a Rule 10b5-1 trading plan. It is reported simply as a purchase of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2026		P		5,000(1)	A	$0.78(1)	373,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.77 to $0.80 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)